Achromatopsia

Achromatopsia is a rare genetic eye condition that affects the retina, the light-sensitive tissue at the back of the eye. Specifically, it impacts the "cone" cells, which are responsible for sharp central vision, seeing colors, and seeing well in bright light. Because these cone cells do not work properly, people with achromatopsia rely almost entirely on their "rod" cells, which are designed for night vision and seeing in dim light. This condition is usually inherited when a child receives a changed gene from both parents. People with complete achromatopsia cannot see any colors at all; they see the world in shades of gray, black, and white. They also experience very blurry vision and extreme sensitivity to light (photophobia), meaning bright daylight can be painful and blinding. In babies, the first signs are often rapid, involuntary eye movements (nystagmus) and a strong dislike of bright lights. There is also an "incomplete" form of the condition where some cone cells still work, resulting in slightly better vision and some ability to see colors. While there is currently no cure for achromatopsia, the condition generally does not get much worse over time, and it does not affect a person's overall health or lifespan. Management focuses on making life more comfortable and maximizing the vision that is present. This includes wearing heavily tinted glasses or special contact lenses to reduce light sensitivity, using magnifying devices for reading, and getting the right prescription glasses. Researchers are actively studying new treatments, including gene therapies, which offer hope for improving vision in the future.

Condition category: Retinal Dystrophy

Prevalence: 1 in 30,000

Inheritance patterns: Autosomal Recessive

Age of onset: Birth to early infancy

Clinical overview: Achromatopsia (ACHM), also known as rod monochromatism or total color blindness, is a rare, autosomal recessive inherited retinal dystrophy characterized by the complete or partial absence of cone photoreceptor function. Cones are the retinal cells responsible for high-acuity central vision, color discrimination, and vision in bright light (photopic vision). The condition is broadly classified into two clinical phenotypes: complete achromatopsia, where there is a total lack of cone function, and incomplete achromatopsia, where some residual cone function remains. The clinical hallmark of achromatopsia includes a triad of symptoms presenting in early infancy: pendular nystagmus, severe photophobia (light sensitivity), and markedly reduced visual acuity. Patients with complete achromatopsia have no color vision, perceiving the world entirely in shades of gray, black, and white. Incomplete achromats may have slightly better visual acuity and some limited color discrimination. The condition is distinct from more common forms of color vision deficiency (such as red-green color blindness), which typically involve defects in only one or two cone types and do not cause severe visual impairment or photophobia. Achromatopsia is genetically heterogeneous, with mutations in at least six genes (CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6) identified as causative. These genes primarily encode proteins essential for the cone phototransduction cascade, the process by which light is converted into electrical signals. The condition is associated with several OMIM entries, including OMIM 216900 (ACHM2, CNGA3-related), OMIM 268000 (ACHM3, CNGB3-related), OMIM 613856 (ACHM4, GNAT2-related), OMIM 610024 (ACHM6, PDE6C-related), OMIM 616517 (ACHM7, PDE6H-related), and OMIM 616224 (ACHM5, ATF6-related). The Orphanet number for achromatopsia is ORPHA49382.

Patient and family guide: Achromatopsia is a rare genetic eye condition that affects the retina, the light-sensitive tissue at the back of the eye. Specifically, it impacts the "cone" cells, which are responsible for sharp central vision, seeing colors, and seeing well in bright light. Because these cone cells do not work properly, people with achromatopsia rely almost entirely on their "rod" cells, which are designed for night vision and seeing in dim light. This condition is usually inherited when a child receives a changed gene from both parents. People with complete achromatopsia cannot see any colors at all; they see the world in shades of gray, black, and white. They also experience very blurry vision and extreme sensitivity to light (photophobia), meaning bright daylight can be painful and blinding. In babies, the first signs are often rapid, involuntary eye movements (nystagmus) and a strong dislike of bright lights. There is also an "incomplete" form of the condition where some cone cells still work, resulting in slightly better vision and some ability to see colors. While there is currently no cure for achromatopsia, the condition generally does not get much worse over time, and it does not affect a person's overall health or lifespan. Management focuses on making life more comfortable and maximizing the vision that is present. This includes wearing heavily tinted glasses or special contact lenses to reduce light sensitivity, using magnifying devices for reading, and getting the right prescription glasses. Researchers are actively studying new treatments, including gene therapies, which offer hope for improving vision in the future.

Symptoms and clinical features: The clinical presentation of achromatopsia is characterized by a classic triad of symptoms that typically become apparent in early infancy: pendular nystagmus, severe photophobia (hemeralopia), and markedly reduced visual acuity. In the early stages (birth to 6 months), parents often notice that the infant has rapid, involuntary eye movements (nystagmus) and exhibits extreme discomfort or avoidance behavior in bright light. The nystagmus is usually pendular and horizontal, though it can have a rotary component. Because the cone photoreceptors are non-functional, the infant relies entirely on rod photoreceptors, which are saturated and blinded by daylight, leading to the profound photophobia. As the child reaches the intermediate stage (early childhood to adolescence), the nystagmus may dampen or become less noticeable, but the visual deficits become more apparent as visual demands increase. Visual acuity in complete achromatopsia is typically 20/200 or worse, while those with incomplete achromatopsia may achieve acuities up to 20/80. A defining feature is the complete or near-complete inability to discriminate colors; patients with complete achromatopsia see the world in shades of gray. Additionally, patients often develop a small central scotoma (blind spot) due to the lack of functioning foveal cones, which may lead to eccentric fixation, where the patient looks slightly away from an object to view it with the rod-rich peripheral retina. High hyperopia (farsightedness) is also a common associated feature. In the advanced stages (adulthood), the functional symptoms of achromatopsia—poor visual acuity, color blindness, and photophobia—generally remain stable. However, some patients may experience a slow, progressive structural degeneration of the macula, which can be observed on imaging. Despite these anatomical changes, the clinical symptoms rarely worsen significantly. The condition is isolated to the eyes, and there are no associated systemic or extraocular features.

Molecular pathology: Achromatopsia is caused by defects in the molecular machinery essential for cone photoreceptor function and survival. The majority of implicated genes (CNGA3, CNGB3, GNAT2, PDE6C, and PDE6H) encode proteins that are critical components of the cone-specific phototransduction cascade. This cascade is the process by which light is converted into an electrical signal in the retina. When light strikes the cone visual pigment, it activates transducin, a G-protein whose alpha subunit is encoded by GNAT2. Activated transducin then stimulates cone phosphodiesterase (PDE6), a complex composed of catalytic subunits (encoded by PDE6C) and inhibitory subunits (encoded by PDE6H). The activation of PDE6 leads to the hydrolysis of cyclic guanosine monophosphate (cGMP), reducing its intracellular concentration. This decrease in cGMP causes the closure of cyclic nucleotide-gated (CNG) cation channels located in the cone outer segment membrane. These channels are heterotetramers composed of three alpha subunits (encoded by CNGA3) and one beta subunit (encoded by CNGB3). The closure of CNG channels stops the influx of positively charged ions (calcium and sodium), resulting in the hyperpolarization of the cone cell membrane and the generation of an electrical signal that is transmitted to the brain. Mutations in any of these phototransduction genes disrupt this delicate cascade. For instance, mutations in CNGA3 or CNGB3 can lead to the production of non-functional or absent CNG channels, preventing the generation of the electrical signal in response to light. This functional loss is accompanied by a slow, progressive degeneration of the cone photoreceptors. The exact mechanism of cell death is not fully understood but is thought to involve the dysregulation of intracellular ion concentrations and subsequent apoptotic pathways. The ATF6 gene represents a distinct molecular mechanism. Unlike the other genes, ATF6 is ubiquitously expressed and encodes a transmembrane transcription factor involved in the unfolded protein response (UPR) pathway within the endoplasmic reticulum (ER). Mutations in ATF6 impair the cell's ability to manage ER stress, leading to increased cell death. It remains unclear why defects in this ubiquitous pathway specifically cause isolated cone dysfunction and foveal hypoplasia in achromatopsia, though it is hypothesized that ATF6 plays a crucial role in foveal cone development.

Genetics: Achromatopsia is primarily inherited in an autosomal recessive pattern, meaning an affected individual must inherit two mutated copies of a causative gene, one from each parent. The condition exhibits significant genetic heterogeneity, with pathogenic variants identified in six genes to date: CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6. Together, mutations in these genes account for approximately 90% of all achromatopsia cases. Mutations in the CNGB3 and CNGA3 genes are the most common, responsible for 50-70% and 25-30% of cases, respectively. The c.1148delC frameshift mutation in CNGB3 is particularly prevalent among individuals of European descent. Other genes account for a smaller fraction of cases: GNAT2 (<2%), PDE6C (<2%), PDE6H (<1%), and ATF6 (1-2%). While most cases are autosomal recessive, rare instances of digenic or triallelic inheritance have been reported, such as patients harboring mutations in both CNGB3 and CNGA3. Genotype-phenotype correlations in achromatopsia are complex. Mutations in the same gene can cause either complete or incomplete forms of the disease, depending on the specific variant and its impact on protein function. For example, certain missense mutations in CNGA3 and CNGB3 may allow for residual channel function, leading to incomplete achromatopsia with some preserved color vision and better visual acuity. Conversely, nonsense or frameshift mutations typically result in a complete loss of function and the more severe complete achromatopsia phenotype. Patients with GNAT2 mutations often have relatively well-preserved cone mosaics, whereas those with PDE6C and ATF6 mutations tend to have severe foveal cone loss.

Diagnostic evaluation: The diagnosis of achromatopsia is based on clinical findings, specialized imaging, and electrophysiological testing. Fundoscopy is often unremarkable in the early stages of the disease, though some patients may exhibit an absent foveal reflex, central retinal pigment epithelium (RPE) mottling, or macular atrophy as the condition progresses. Foveal hypoplasia is also a common finding, particularly in patients with mutations in CNGA3, CNGB3, or ATF6. Optical coherence tomography (OCT) is a critical tool for evaluating the structural integrity of the macula. Typical OCT findings include outer retinal attenuation, disruption or absence of the ellipsoid zone, and a hyporeflective "optical gap" corresponding to the loss of foveal photoreceptor outer segments. Over time, this may progress to outer nuclear layer loss and complete RPE disruption. Fundus autofluorescence (FAF) imaging may show varying patterns, ranging from normal to central hypoautofluorescence or a hyperautofluorescent ring surrounding the fovea. The gold standard for diagnosing achromatopsia is full-field electroretinography (ERG). In complete achromatopsia, cone-mediated responses (photopic ERG and 30 Hz flicker) are markedly reduced or entirely absent, while rod-mediated responses (scotopic ERG) are typically normal or only slightly subnormal. Multifocal ERG, which isolates macular function, is often more sensitive than full-field ERG. Differential diagnosis includes blue cone monochromatism, Leber congenital amaurosis, cone dystrophy, and ocular albinism. Genetic testing is essential to confirm the diagnosis and identify the specific causative mutation.

Differential diagnosis: Differential diagnosis of achromatopsia includes: (1) Blue cone monochromatism — X-linked, preserved S-cone (blue) function on ERG, OPN1LW/OPN1MW mutations. (2) Cone dystrophy (progressive) — later onset, progressive deterioration, initially normal color vision. (3) Leber congenital amaurosis — more severe, absent rod and cone ERG responses. (4) Congenital stationary night blindness — night blindness predominates, preserved cone function. (5) Ocular albinism — nystagmus with iris transillumination, foveal hypoplasia, no absent cone ERG. (6) Aniridia — iris hypoplasia, PAX6 mutations, foveal hypoplasia. (7) Rod monochromatism (incomplete achromatopsia) — some residual cone function preserved.

Natural history: Achromatopsia is generally considered a stationary or very slowly progressive retinal dystrophy. Symptoms typically manifest at birth or in early infancy, with parents often noticing nystagmus and extreme light sensitivity (photophobia) within the first few months of life. The nystagmus may improve slightly over time, but the visual acuity deficit and color vision impairment remain relatively stable throughout childhood and adulthood. While the functional symptoms (visual acuity and color vision) are largely stable, recent high-resolution imaging studies using OCT have revealed that achromatopsia may involve a slow, age-related structural degeneration of the macula. Many patients exhibit progressive changes in the foveal architecture, such as the disruption of the ellipsoid zone, the development of a hyporeflective "optical gap," and eventual outer retinal and RPE atrophy. However, these structural changes do not always correlate with a significant decline in visual function. The prognosis for patients with achromatopsia is generally stable regarding visual acuity, which typically remains in the range of 20/200 or worse for complete achromatopsia. The condition does not affect life expectancy or cause systemic health issues. However, the severe photophobia and poor visual acuity can significantly impact the quality of life, requiring lifelong use of low vision aids and adaptations for bright environments.

Management and treatment research: ### Current management There is currently no cure for achromatopsia. Care focuses on reducing symptoms, making the most of remaining vision, and supporting daily activities, education, and independence. - **Light sensitivity management:** Photophobia, or painful or disabling sensitivity to light, is a central feature of achromatopsia. Dark or selectively tinted glasses, tinted contact lenses, hats, visors, and other light-control strategies may improve comfort and function outdoors and in bright indoor settings. Red or brown filters can be helpful for some people. - **Refraction and vision correction:** Regular eye examinations and an up-to-date glasses or contact lens prescription can correct refractive errors such as farsightedness, nearsightedness, or astigmatism. - **Low-vision services:** Magnifiers, telescopes, electronic reading devices, screen magnification, high-contrast settings, and accessibility features may support reading and other visually demanding tasks. - **School and workplace accommodations:** Large-print or digital materials, preferential seating, controlled lighting, extra time for visually based tasks, and orientation and mobility support may be useful. - **Genetic testing and counseling:** Genetic testing can help confirm the diagnosis, identify the responsible gene, inform family-planning discussions, and determine whether a person may be eligible for gene-specific research studies. ### Approved therapies There are no approved gene therapies or other disease-modifying treatments specifically for achromatopsia. ### Investigational gene therapy Most gene-therapy research in achromatopsia aims to restore function in cone photoreceptors. Cones are retinal cells needed for color vision, sharp central vision, and vision in brighter light. These studies may use an adeno-associated virus (AAV), a modified virus that can deliver a working copy of a gene to retinal cells. - **CNGA3-associated achromatopsia:** **rAAV.hCNGA3**, also known as **AGTC-402**, is an AAV-mediated gene augmentation therapy designed to deliver a functional copy of the *CNGA3* gene to cone photoreceptors. - The Phase 1/2 study, **NCT02610582**, is active but not recruiting. - The study is evaluating the safety and potential effects of treatment in people with achromatopsia caused by disease-causing variants in *CNGA3*. Gene therapy for achromatopsia remains investigational. Participation in a clinical study does not establish that a treatment is effective, and possible benefits and risks are still being evaluated. ### Clinical trial participation Clinical research may include treatment trials, natural-history studies, genetic studies, and registries. Natural-history studies follow participants over time to better understand how inherited retinal diseases affect vision and to help researchers design future studies. Registries and genetic-data studies may also help connect people with future research opportunities. Recruiting studies that may include people with achromatopsia or other inherited retinal diseases include: - **NCT06491615:** National Ophthalmic Genotyping and Phenotyping Network (eyeGENE), a National Eye Institute genetic and clinical data repository study. - **NCT02435940:** Inherited Retinal Degenerative Disease Registry, sponsored by the Foundation Fighting Blindness. - **NCT07085533:** Natural History Study of Inherited Retinal Diseases. Eligibility can depend on the genetic diagnosis, age, retinal findings, location, and other study requirements. A retina specialist or genetic counselor can help interpret genetic testing results and identify appropriate research opportunities.

Outlook: The visual prognosis for individuals with achromatopsia is generally stable, with visual acuity typically remaining in the range of 20/200 or worse for those with the complete form of the disorder. While recent imaging studies have shown slow, age-related structural changes in the macula, these anatomical alterations do not usually translate into a significant, rapid decline in visual function. Patients typically maintain the level of vision they develop during childhood throughout their lives. Quality of life is primarily affected by severe photophobia and reduced visual acuity, which can present challenges in educational, occupational, and social settings. Activities requiring fine detail vision, such as reading small print or driving, are often difficult or impossible without specialized aids. However, with appropriate supportive care—including heavily tinted lenses to manage light sensitivity, low vision aids, and educational accommodations—individuals with achromatopsia can lead independent and fulfilling lives. The condition is strictly ocular and does not impact life expectancy or general health.

Epidemiology: Achromatopsia is a rare genetic disorder with an estimated worldwide prevalence of approximately 1 in 30,000 to 1 in 50,000 live births. The condition affects both males and females equally, as it is primarily inherited in an autosomal recessive manner. Complete achromatopsia is more common than the incomplete form. There are notable geographic and ethnic variations in the prevalence of specific genetic mutations. For instance, mutations in the CNGB3 gene are the most frequent cause of achromatopsia in populations of European descent, accounting for up to 50% of cases, largely due to a common founder mutation (c.1148delC). Conversely, CNGA3 mutations are more prevalent in the Middle East and China. An exceptionally high prevalence of achromatopsia is observed among the Pingelapese islanders of Micronesia, where up to 10% of the population is affected due to a founder effect involving a specific CNGB3 mutation.

Selected references: 1. Kohl S, Jägle H, Wissinger B, Zobor D. Achromatopsia. 2004 Jun 24 [Updated 2018 Sep 20]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. PMID: 20301591 2. Michalakis S, Gerhardt M, Rudolph G, Priglinger S, Priglinger C. Achromatopsia: Genetics and Gene Therapy. Mol Diagn Ther. 2022 Jan;26(1):51-59. PMID: 34860343 3. Aboshiha J, Dubis AM, Carroll J, Hardcastle AJ, Michaelides M. The cone dysfunction syndromes. Br J Ophthalmol. 2016 Jan;100(1):115-21. PMID: 25770143 4. Remmer MH, Rastogi N, Ranka MP, Ceisler EJ. Achromatopsia: a review. Curr Opin Ophthalmol. 2015 Sep;26(5):333-40. PMID: 26214418 5. Hirji N, Aboshiha J, Georgiou M, Bainbridge J, Michaelides M. Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options. Ophthalmic Genet. 2018 Apr;39(2):149-157. PMID: 29303385 6. Fahim AT, Khan NW, Zahid S, et al. Diagnostic fundus autofluorescence patterns in achromatopsia. Am J Ophthalmol. 2013 Dec;156(6):1211-1219.e2. PMID: 23972307 7. Eshel YM, Abaev O, Yahalom C. Achromatopsia: Long term visual performance and clinical characteristics. Eur J Ophthalmol. 2024 May;34(3):834-841. PMID: 37933615 8. Michaelides M, Hirji N, Wong SC, et al. First-in-Human Gene Therapy Trial of AAV8-hCARp.hCNGB3 in Adults and Children With CNGB3-Associated Achromatopsia. Am J Ophthalmol. 2023 Sep;253:243-251. PMID: 37182695